Xinyi Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xinyi Xu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Cannas Kwok
School of Nursing, Paramedicine and Healthcare Sciences. Charles Sturt University, Panorama Avenue. Wiradjuri Country, Bathurst, New South Wales, Australia
1 shared publication - Chao Shen
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China
1 shared publication Chun-Min Wu
School of Nursing, Nanjing Medical University, China
1 shared publication- Fengbo Wu
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China
1 shared publication - Haoyang Hu
The State Key Laboratory of Chemical Engineering and Low-carbon Technology, Department of Chemical Engineering, Tsinghua University, Beijing, China
1 shared publication Juan Cao
Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
1 shared publication
Latest Publications
- 19 May 2026
- Published by Elsevier in Social Science & Medicine
- Vol. 403, 119422
Care, commerce, and conflict: A multimodal discourse analysis of dietary guidance for gastrointestinal cancer survivors on Xiaohongshu
- 19 May 2026
- Published by Elsevier in Social Science & Medicine
- Vol. 403, 119422
Care, commerce, and conflict: A multimodal discourse analysis of dietary guidance for gastrointestinal cancer survivors on Xiaohongshu
- Open Access
- 29 May 2025
- Published by Wiley in Health Promotion Journal of Australia
- Vol. 36 (3) , e70059
Co‐Designed Culturally Tailored Cancer Screening Promotion Program With Chinese‐Australian: Using a Community Partnership Approach
Issue Addressed: Despite national cancer screening programs in Australia, people from culturally and linguistically diverse (CALD) backgrounds, particularly Chinese‐Australians, demonstrate significantly lower participation rates in cancer screening. Cultural beliefs, language barriers and limited health literacy contribute to this disparity, highlighting the need for culturally tailored interventions.Methods: A culturally tailored cancer awareness education and screening promotion program was developed and implemented using a community partnership approach. A consumer engagement panel comprising Chinese community members, cancer survivors and community leaders was established to guide program development and implementation. Twenty‐four educational sessions were delivered in Cantonese or Mandarin to 821 Chinese‐Australians. The program's effectiveness was evaluated using pre‐ and post‐intervention questionnaires assessing cancer knowledge, screening awareness and screening intentions.Results: Significant improvements were observed in participants' awareness of screening practices (bowel screening: 50.1% to 100%; breast awareness: 78.8% to 100%; mammogram: 65.8% to 95.6%; cervical screening: 86.5% to 96.9%). Screening intentions within 6 months increased substantially across all cancer types (bowel: 7.4% to 37%; breast awareness: 21.2% to 77.6%; mammogram: 18.9% to 47.7%; cervical: 39.8% to 73.1%). About 9 out of 13 questions regarding cancer knowledge and beliefs showed significant improvement post‐intervention.Conclusions: The community partnership approach and culturally tailored cancer education effectively improved cancer screening awareness and intentions among Chinese‐Australians.So What?: This study provides a successful model for developing and implementing culturally sensitive cancer screening promotion programmes, which can be adapted for other CALD communities to address health disparities in cancer screening participation.
- 29 May 2025
- Published by Wiley in Health Promotion Journal of Australia
- Vol. 36 (3) , e70059
Open AccessCo‐Designed Culturally Tailored Cancer Screening Promotion Program With Chinese‐Australian: Using a Community Partnership Approach
Issue Addressed: Despite national cancer screening programs in Australia, people from culturally and linguistically diverse (CALD) backgrounds, particularly Chinese‐Australians, demonstrate significantly lower participation rates in cancer screening. Cultural beliefs, language barriers and limited health literacy contribute to this disparity, highlighting the need for culturally tailored interventions.Methods: A culturally tailored cancer awareness education and screening promotion program was developed and implemented using a community partnership approach. A consumer engagement panel comprising Chinese community members, cancer survivors and community leaders was established to guide program development and implementation. Twenty‐four educational sessions were delivered in Cantonese or Mandarin to 821 Chinese‐Australians. The program's effectiveness was evaluated using pre‐ and post‐intervention questionnaires assessing cancer knowledge, screening awareness and screening intentions.Results: Significant improvements were observed in participants' awareness of screening practices (bowel screening: 50.1% to 100%; breast awareness: 78.8% to 100%; mammogram: 65.8% to 95.6%; cervical screening: 86.5% to 96.9%). Screening intentions within 6 months increased substantially across all cancer types (bowel: 7.4% to 37%; breast awareness: 21.2% to 77.6%; mammogram: 18.9% to 47.7%; cervical: 39.8% to 73.1%). About 9 out of 13 questions regarding cancer knowledge and beliefs showed significant improvement post‐intervention.Conclusions: The community partnership approach and culturally tailored cancer education effectively improved cancer screening awareness and intentions among Chinese‐Australians.So What?: This study provides a successful model for developing and implementing culturally sensitive cancer screening promotion programmes, which can be adapted for other CALD communities to address health disparities in cancer screening participation.
- Open Access
- 13 June 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1158274
Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials
Aims: As the impact of inclisiran in stroke prevention in atherosclerotic cardiovascular disease (ASCVD) patients or those at high risk of ASCVD is still unclear, we conducted a systematic review and meta-analysis of randomized controlled trials (RCT) to quantify the effectiveness of inclisiran in stroke prevention in these patients.Methods: Literature research was conducted in four electronic databases (PubMed, EMBASE, Web of Science, CENTRAL) and two clinical trials registers (ClinicalTrials.gov, WHO ICTRP) from the inception of the study to 17 October 2022, and was updated by the end of the study on 5 January 2023. Two authors independently screened the studies, extracted the data, and assessed the bias. The risk of bias was assessed using the Cochrane risk-of-bias tool for randomized trials (RoB 2). The intervention effect was estimated by calculating risk ratio (RR), weighted mean difference (WMD), and 95% confidence interval (CI) with R 4.0.5. Sensitivity analysis by changing meta-analysis model was also performed to test the robustness of the pooled results. If this was not possible, a descriptive analysis was conducted.Results: Four RCTs (n = 3,713 patients) were rated as high-risk bias. Meta-analysis of three RCTs (ORION-9, ORION-10, and ORION-11) showed that inclisiran reduced myocardial infarction (MI) risk by 32% (RR = 0.68, 95%CI = 0.48–0.96) but did not reduce stroke (RR = 0.92, 95%CI = 0.54–1.58) and major cardiovascular events (MACE) (RR = 0.81, 95%CI = 0.65–1.02) risk. Sensitivity analysis results were stable. Safety was similar to the placebo group but had frequent injection-site reactions (RR = 6.56, 95%CI = 3.83–11.25), which were predominantly mild or moderate. A descriptive analysis of one RCT (ORION-5) was conducted due to different study designs, and suggested that inclisiran might be given semiannually from the beginning.Conclusion: Inclisiran is not beneficial for stroke or MACE prevention in ASCVD or patients at high risk of ASCVD but is associated with the reduction of MI. Given the limited number and quality of the available studies and the lack of a standardized definition for cardiovascular events, further studies are essential for confirming the results.
- 13 June 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1158274
Open AccessEfficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials
Aims: As the impact of inclisiran in stroke prevention in atherosclerotic cardiovascular disease (ASCVD) patients or those at high risk of ASCVD is still unclear, we conducted a systematic review and meta-analysis of randomized controlled trials (RCT) to quantify the effectiveness of inclisiran in stroke prevention in these patients.Methods: Literature research was conducted in four electronic databases (PubMed, EMBASE, Web of Science, CENTRAL) and two clinical trials registers (ClinicalTrials.gov, WHO ICTRP) from the inception of the study to 17 October 2022, and was updated by the end of the study on 5 January 2023. Two authors independently screened the studies, extracted the data, and assessed the bias. The risk of bias was assessed using the Cochrane risk-of-bias tool for randomized trials (RoB 2). The intervention effect was estimated by calculating risk ratio (RR), weighted mean difference (WMD), and 95% confidence interval (CI) with R 4.0.5. Sensitivity analysis by changing meta-analysis model was also performed to test the robustness of the pooled results. If this was not possible, a descriptive analysis was conducted.Results: Four RCTs (n = 3,713 patients) were rated as high-risk bias. Meta-analysis of three RCTs (ORION-9, ORION-10, and ORION-11) showed that inclisiran reduced myocardial infarction (MI) risk by 32% (RR = 0.68, 95%CI = 0.48–0.96) but did not reduce stroke (RR = 0.92, 95%CI = 0.54–1.58) and major cardiovascular events (MACE) (RR = 0.81, 95%CI = 0.65–1.02) risk. Sensitivity analysis results were stable. Safety was similar to the placebo group but had frequent injection-site reactions (RR = 6.56, 95%CI = 3.83–11.25), which were predominantly mild or moderate. A descriptive analysis of one RCT (ORION-5) was conducted due to different study designs, and suggested that inclisiran might be given semiannually from the beginning.Conclusion: Inclisiran is not beneficial for stroke or MACE prevention in ASCVD or patients at high risk of ASCVD but is associated with the reduction of MI. Given the limited number and quality of the available studies and the lack of a standardized definition for cardiovascular events, further studies are essential for confirming the results.